Related Experiment Video
Updated: Jun 27, 2025
11:08
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
742
Recent advances in hepatocellular carcinoma-targeted nanoparticles
Xiaoming Liu1,2, Yaowei Bai1,2, Binqian Zhou3
1Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
Biomedical Materials (Bristol, England)
|May 2, 2024
Summary
Nanotechnology offers a promising approach to improve hepatocellular carcinoma (HCC) treatment by enhancing drug delivery and reducing toxicity. Further research into nanodelivery systems and active targeting is crucial for advancing precision HCC therapy.
Area of Science:
- Medicine
- Oncology
- Nanotechnology
Background:
- Hepatocellular carcinoma (HCC) presents a significant global health challenge with suboptimal treatment outcomes.
- Current treatments like immunotherapy and targeted therapy face challenges in drug delivery, targeting, release, and toxicity.
- Nanotechnology has emerged as a potential solution to enhance precision therapy for HCC.
Purpose of the Study:
- To explore the potential of nanotechnology in improving HCC treatment.
- To identify challenges and future directions for nanodelivery systems in HCC therapy.
Main Methods:
- Review of current advancements in nanotechnology for HCC treatment.
- Discussion of challenges in clinical translation of drug-loaded nanoparticles (NPs).
Main Results:
- Nanotechnology can increase local drug concentration in tumors and reduce systemic toxicity.
- Drug-loaded NPs show potential for enhancing the effectiveness of precision HCC therapy.
- Challenges remain in the clinical translation of NPs for HCC treatment.
Conclusions:
- Nanodelivery systems and active targeting NP designs are critical for future HCC drug development.
- Combining interventional therapies with drug-loaded NPs can significantly advance precision HCC therapy.
